| Date | Title | Description |
| 04.11.2024 | BioStock: Medivir signs new clinical trial collaboration with Eisai | BioStock: Medivir signs new clinical trial collaboration with Eisai
Mon, Nov 04, 2024 16:41 CET Report this content
Medivir has entered into a clinical trial collaboration and supply agreement with Eisai to evaluate its liver-targeted treat... |
| 03.11.2024 | Lecanemab: A Beacon of Hope in Alzheimer’s Treatment | In the labyrinth of Alzheimer’s disease, a new light flickers. Lecanemab, a monoclonal antibody, has emerged as a promising treatment, showing potential to slow cognitive decline in early-stage patients. Recent data presented at the Clinica... |
| 01.11.2024 | Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US | Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Fri, Nov 01, 2024 00:30 CET Report this content
Stockholm, Sweden November 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: ... |
| 31.10.2024 | The Rise of Leqembi: A New Dawn in Alzheimer’s Treatment | In the world of Alzheimer’s research, a beacon of hope shines brighter than ever. Leqembi, a drug developed through a partnership between BioArctic and Eisai, is making waves. The latest reports reveal that Leqembi generated JPY 10 billion ... |
| 31.10.2024 | Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile | Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
Thu, Oct 31, 2024 08:30 CET Report this content
Stockholm, Sweden October 31, 2024 – BioArctic AB’... |
| 30.10.2024 | Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease | Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
Wed, Oct 30, 2024 08:30 CET Report this content
Stockholm, Sweden, October 30, 2024 – BioArctic AB (publ) (Na... |
| 30.10.2024 | Leqembi® revenue totaled JPY 10 billion in the third quarter 2024 | Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
Wed, Oct 30, 2024 11:45 CET Report this content
Stockholm, Sweden, October 30, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preli... |
| 30.10.2024 | Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference | -New testing method highlights link between protofibrils and biomarkers for neurodegeneration-
-Patient and caregiver perspectives on five-year treatment with lecanemab -
- Utilization of blood biomarkers to predict brain amyloid accumulati... |
| 29.10.2024 | Massachusetts: The Beacon of Sustainable Biotech Innovation | Massachusetts is a powerhouse in biotechnology. It’s a state where innovation blooms like spring flowers. The rich soil of education, research, and collaboration nurtures groundbreaking advancements. This article explores how Massachusetts ... |
| 24.10.2024 | Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD | Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
Thu, Oct 24, 2024 08:00 CET Report this content
Stockholm, October 24, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented wit... |
| 17.10.2024 | BioArctic and Eisai: Navigating the Waters of Alzheimer’s Treatment | In the world of biopharma, few stories resonate as powerfully as the quest to combat Alzheimer’s disease. BioArctic AB, a Swedish company, stands at the forefront of this battle. Their flagship product, Leqembi® (lecanemab), has emerged as ... |
| 17.10.2024 | Eisai will request reconsideration of initial decision for lecanemab in Australia | Eisai will request reconsideration of initial decision for lecanemab in Australia
Thu, Oct 17, 2024 01:30 CET Report this content
Stockholm, Sweden October 17, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced to... |
| 07.10.2024 | Operationalizing Innovative Biomarkers to Support Evolving Therapeutic and Diagnostic Landscape for Neurodegenerative Diseases, Upcoming Webinar Hosted by Xtalks | www.labcorp.com
In this free webinar, learn about the rapidly evolving landscape of Alzheimer's disease therapy development and treatment. Attendees will gain insights into the key considerations for various platforms and strategies to inco... |
| 03.10.2024 | Virtual dementia care platform Rippl scores $23M | Photo: Halfpoint Images/Getty Images
Rippl, a company focused on providing mental health solutions to seniors with dementia and other cognitive conditions, announced it closed a $23 million Series A funding round.
Tina Hoang-To, Kin Venture... |
| 30.09.2024 | Number of shares and votes in BioArctic AB (publ) as of September 30, 2024 | Number of shares and votes in BioArctic AB (publ) as of September 30, 2024
Mon, Sep 30, 2024 18:30 CET Report this content
Stockholm, September 30, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company durin... |
| 17.09.2024 | BioStock: Medivir – live from ESMO in Barcelona | BioStock: Medivir – live from ESMO in Barcelona
Tue, Sep 17, 2024 15:45 CET Report this content
At the ESMO conference in Barcelona, Medivir presented mature results from its ongoing Phase Ib/IIa trial of fostrox in combination with Lenvima... |
| 09.09.2024 | Пионер ксенотрансплантации eGenesis собрал $191 млн для генно-редактированных органов свиньи | Компания eGenesis уже попала в заголовки новостей благодаря трансплантации органов свиньи. В марте 2024 года eGenesis объявила о первой в мире успешной пересадке почки свиньи живому пациенту. Трансплантация была одобрена FDA в рамках расшир... |
| 04.09.2024 | eGenesis Raises $191M in Series B Funding | eGenesis, a Cambridge, MA-based biotechnology company developing human-compatible engineered organs to address the global organ shortage, raised $191M in Series B funding.
The round was led by Lux Capital, with participation from existing i... |
| 04.09.2024 | eGenesis: $191 Million (Series D) Secured To Develop Engineered Organs For Addressing Transplant Shortages | eGenesis, a biotechnology company that is developing human-compatible engineered organs to address the global organ shortage, announced today the closing of a $191 million Series D financing. The funding was led by Lux Capital, with partici... |
| 29.08.2024 | Interim Report for the period April – June 2024 | Interim Report for the period April – June 2024
Thu, Aug 29, 2024 08:00 CET Report this content
Lecanemab authorised in Great Britain and EU re-examination in progress
Events during the second quarter 2024 BioArctic and Eisai entered into a... |
| 27.08.2024 | Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology | Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology
Tue, Aug 27, 2024 08:00 CET Report this content
Stockholm, August 27, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced toda... |
| 22.08.2024 | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain
Thu, Aug 22, 2024 11:05 CET Report this content
Stockholm, Sweden August 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today t... |
| 19.08.2024 | Invitation to presentation of BioArctic’s second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET
Mon, Aug 19, 2024 08:30 CET Report this content
Stockholm, Sweden, August 15, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: ... |
| 14.08.2024 | Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates | Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates
Wed, Aug 14, 2024 01:00 CET Report this content
Stockholm, Sweden, August 14, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announ... |
| 01.08.2024 | Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024 | Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024
Thu, Aug 01, 2024 12:45 CET Report this content
Stockholm, Sweden, August 1, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today ... |
| 31.07.2024 | Lecanemab: A Beacon of Hope in the Fight Against Alzheimer’s Disease | In the battle against Alzheimer’s disease, a new warrior has emerged: lecanemab, marketed as LEQEMBI. Recent findings presented at the Alzheimer’s Association International Conference (AAIC) 2024 reveal that this dual-acting antibody is not... |
| 30.07.2024 | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz... | 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
Clinical Data and Biomarkers Show Alzheimer’s Disease Does Not Stop Progressing Aft... |
| 30.07.2024 | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz... | 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
Clinical Data and Biomarkers Show Alzheimer’s Disease Does Not Stop Progressing Aft... |
| 30.07.2024 | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alz... | - 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
- Clinical Data and Biomarkers Show Alzheimer's Disease Does Not Stop Progressing... |
| 30.07.2024 | Long-term lecanemab data show increased patient benefit with maintained safety profile | Long-term lecanemab data show increased patient benefit with maintained safety profile
Tue, Jul 30, 2024 23:00 CET Report this content
Stockholm, Sweden July 30, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today pr... |
| 30.07.2024 | Is it worth spending RMB 200,000 a year to delay the onset of Alzheimer’s disease? | The loss of control can strike out of the blue, even when preceded by minor symptoms.
When Zhang Li’s mother began experiencing symptoms like dizziness and poor memory, it was initially dismissed as a mild stroke—a minor ailment. However, o... |
| 27.07.2024 | Lecanemab's EU Setback: A Race Against Time for Alzheimer's Treatment | In a world where time is a precious commodity, the recent decision by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has sent ripples of disappointment through the Alzheimer’s community. On ... |
| 27.07.2024 | The Future of Brain Health: Innovations and Leadership in Alzheimer's and Multiple Sclerosis Treatments | In the ever-evolving landscape of biotechnology, two companies are making waves in the treatment of chronic neurological diseases: Immunic, Inc. and Neurophet. Both are leveraging advanced technologies and seasoned leadership to tackle the ... |
| 27.07.2024 | Lecanemab: A Beacon of Hope in Alzheimer’s Treatment | The Alzheimer’s Association International Conference (AAIC) 2024 is set to unveil groundbreaking data on lecanemab, a drug that could reshape the landscape of Alzheimer’s disease (AD) treatment. As the conference approaches, excitement is p... |
| 26.07.2024 | Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union | TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 26.07.2024 | CHMP has adopted a negative opinion on lecanemab for the EU | CHMP has adopted a negative opinion on lecanemab for the EU
Fri, Jul 26, 2024 12:40 CET Report this content
Stockholm, Sweden July 26, 2024 – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) h... |
| 26.07.2024 | Eisai will seek re-examination of CHMP opinion för lecanemab | Eisai will seek re-examination of CHMP opinion för lecanemab
Fri, Jul 26, 2024 13:15 CET Report this content
Stockholm, Sweden July 26, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will req... |
| 26.07.2024 | Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union | TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 25.07.2024 | Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024 | - Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla
- Introduces updated version of Neurophet SCALE PET with centiloid scale feature
SEOUL, South Korea, July 25, 2024 /PRNewswire/ -- Neurophet, an artificial intel... |
| 25.07.2024 | Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024 | - Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla
- Introduces updated version of Neurophet SCALE PET with centiloid scale feature
SEOUL, South Korea, July 25, 2024 /PRNewswire/ -- Neurophet, an artificial intel... |
| 23.07.2024 | Long-term treatment data for lecanemab to be presented at AAIC 2024 | Long-term treatment data for lecanemab to be presented at AAIC 2024
Tue, Jul 23, 2024 08:00 CET Report this content
Stockholm, July 23, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that its partner Eisai will presen... |
| 22.07.2024 | EISAI TO PRESENT DUAL-ACTING LECANEMAB THREE YEAR EFFICACY AND SAFETY DATA AND DISCUSS LONG-TERM OUTCOMES OF CONTINUED TREATMENT AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2024 | Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline will be shared, including the importance of continued treatment of AD, which is a progressive neurodegenerative disease that begins before plaque deposition and continues... |
| 12.07.2024 | Leqembi approved for the treatment of Alzheimer’s disease in Israel | Leqembi approved for the treatment of Alzheimer’s disease in Israel
Fri, Jul 12, 2024 01:30 CET Report this content
Stockholm, Sweden, July 12, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqem... |
| 11.07.2024 | Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong | Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong
Thu, Jul 11, 2024 01:30 CET Report this content
Stockholm, Sweden, July 11, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that th... |
| 03.07.2024 | FDA Approves New Alzheimer's Drug, Bringing Hope of Slowing Disease for US Patients | By Inno Flores
Published Jul 3, 2024 4:14AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard Share on Pocket
The US Food and Drug Administration (FDA) gave a green light to a new Alzheimer's drug t... |
| 03.07.2024 | FDA approves new Alzheimer's treatment, donanemab from Eli Lilly | The Food and Drug Administration approved a new Alzheimer's treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain's decline in patients facing the early stages of t... |
| 02.07.2024 | Lilly's Alzheimer's drug gets FDA nod | figcaption>span]:font-sans" data-chromatic="ignore">
The Food and Drug Administration granted approval to Eli Lilly's Alzheimer's drug, which was found to slow progression of the disease by about a third, the company an... |
| 28.06.2024 | Leqembi[®] (lecanemab) launched in China | Leqembi[®] (lecanemab) launched in China
Fri, Jun 28, 2024 01:30 CET Report this content
Stockholm, Sweden, June 28, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that Leqembi® (brand name in Ch... |
| 28.06.2024 | Number of shares and votes in BioArctic AB (publ) as of June 28, 2024 | Number of shares and votes in BioArctic AB (publ) as of June 28, 2024
Fri, Jun 28, 2024 18:30 CET Report this content
Stockholm, June 28, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during June iss... |
| 27.06.2024 | “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China | TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 25.06.2024 | TPG: Significant Strategic Growth Investment In K2 Medical Research | Leading global alternative asset management firm TPG announced a significant strategic growth investment in K2 Medical Research, an integrated clinical trial site platform that specializes in central nervous system (CNS) trials for leading ... |
| 17.06.2024 | CARINGKIND RAISES $1.4 MILLION IN SUPPORT OF ALZHEIMER'S AND RELATED DEMENTIA CARE AT THE 28TH ANNUAL FORGET-ME-NOT GALA | NEW YORK, June 17, 2024 /PRNewswire/ -- CaringKind, the trusted partner in Alzheimer's and related dementia caregiving for over 45 years, hosted their 28th annual Forget-Me-Not Gala on Monday, June 3rd, 2024, at Cipriani 42nd Street. The no... |
| 14.06.2024 | Mission Based Media Launches "Health UNMUTED PLUS" for Ad-Free, Early Access on Apple Podcasts | New Subscription Service Empowers Listeners to Support Audio-First Health Information
NEW YORK, June 14, 2024 /PRNewswire/ -- Mission Based Media, a leading creator, producer and distributor of audio-first health education content, today an... |
| 10.06.2024 | WWDC 2024 Highlights: iOS 18 Brings Enhanced Privacy Controls to iPhone | By Quincy Jon
Published Jun 10, 2024 9:26PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard Share on Pocket
The Food and Drug Administration's (FDA) advisory committee endorsed Monday (June 10) El... |
| 10.06.2024 | FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s Disease | FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s Disease
Mon, Jun 10, 2024 01:30 CET Report this content
Stockholm, Sweden, June 10, 2024 – BioArctic AB’s (publ) (Nasdaq... |
| 10.06.2024 | Lilly's Alzheimer's drug faces delayed reckoning | figcaption>span]:font-sans" data-chromatic="ignore">
The outlook for the latest experimental drug shown to delay Alzheimer's disease will come into focus Monday, when Food and Drug Administration advisers review an appl... |
| 24.05.2024 | Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea | Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea
Fri, May 24, 2024 12:55 CET Report this content
Stockholm, Sweden, May 24, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the Ministry o... |
| 22.05.2024 | Bulletin from the Annual General Meeting in BioArctic AB (publ) | Bulletin from the Annual General Meeting in BioArctic AB (publ)
Wed, May 22, 2024 18:00 CET Report this content
Stockholm, 22 May 2024. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today... |
| 17.05.2024 | Interim Report for the period January – March 2024 | Interim Report for the period January – March 2024
Fri, May 17, 2024 08:00 CET Report this content
First BrainTransporter technology agreement signed
Events during the first quarter 2024 Leqembi® was approved for the treatment of Alzheimer'... |
| 15.05.2024 | Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025) | Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025)
Wed, May 15, 2024 05:45 CET Report this content
Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) part... |
| 15.05.2024 | Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing | Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing
Wed, May 15, 2024 01:30 CET Report this content
Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasda... |
| 14.05.2024 | Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track St... | TOKYO and CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbac... |
| 09.05.2024 | Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-Based Institutions | TOKYO, May 9, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria an... |
| 07.05.2024 | Invitation to presentation of BioArctic’s first quarter report for January - March 2024 on May 17 at 9:30 a.m. CET | Invitation to presentation of BioArctic’s first quarter report for January - March 2024 on May 17 at 9:30 a.m. CET
Tue, May 07, 2024 08:30 CET Report this content
Stockholm, Sweden, May 7, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA ... |
| 25.04.2024 | PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono | PRISM BioLab will utilize PepMetics®, innovative small molecules that mimic three-dimensional structures of alpha-helix and beta-turns of peptides for drug discovery against oncology target selected by Ono
TOKYO, April 25, 2024 /PRNewswire/... |
| 24.04.2024 | Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024 | Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
Wed, Apr 24, 2024 12:45 CET Report this content
Stockholm, Sweden, April 24, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preli... |
| 20.04.2024 | BioArctic and Eisai sign research evaluation agreement regarding BAN2802 | BioArctic and Eisai sign research evaluation agreement regarding BAN2802
Sat, Apr 20, 2024 09:40 CET Report this content
Stockholm, Sweden, April 20, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB an... |
| 18.04.2024 | BioArctic publishes the Annual Report for 2023 | BioArctic publishes the Annual Report for 2023
Thu, Apr 18, 2024 08:00 CET Report this content
Stockholm April 18, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for 2023 has been published.
Th... |
| 10.04.2024 | BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm | BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm
Wed, Apr 10, 2024 08:00 CET Report this content
Stockholm, Sweden, April 10, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: ... |
| 01.04.2024 | Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed | Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed
Mon, Apr 01, 2024 01:40 CET Report this content
Stockholm, Sweden, April 1, 2024 – BioArctic AB’... |
| 22.03.2024 | Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons | Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
Fri, Mar 22, 2024 12:30 CET Report this content
Stockholm, Sweden March 22, 2024 – BioArctic AB:... |
| 19.03.2024 | Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease | Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease
Tue, Mar 19, 2024 08:00 CET Report this content
Stockholm, Sweden, March 19, 2024 – B... |
| 11.03.2024 | New data on lecanemab presented at the 2024 AD/PD™ congress | New data on lecanemab presented at the 2024 AD/PD™ congress
Mon, Mar 11, 2024 08:00 CET Report this content
Stockholm, March 11, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and its partner Eisai presented new data on lecanemab (br... |
| 08.03.2024 | FDA delays action on Lilly's Alzheimer's drug | The Food and Drug Administration is asking outside advisors to review the safety and efficacy of an experimental Alzheimer's drug from Eli Lilly that was expected to be approved in the first quarter of this year.
Why it matters: Donanemab w... |
| 07.03.2024 | BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference | BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference
Thu, Mar 07, 2024 06:30 CET Report this content
Stockholm, Sweden, March 7, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) part... |
| 07.03.2024 | HAPPY WOMAN Executive Committee/Eisai Co., Ltd. Consumer hhc Division Gender equality issues to consider on Int ernational Women’s Day What is the number one thing women feel about gender inequality? ... | HAPPY WOMAN Executive Committee/Eisai Co., Ltd. Consumer hhc Division [Gender equality issues to consider on International Women’s Day] What is the number one thing women feel about gender inequality?
“Percentage of housework burden at home... |
| 06.03.2024 | HAPPY WOMAN Executive Committee International Women’s Day Seminar Mama Ogi will also be on stage! Improving self-esteem is the key to promoting women’s empowerment – The importance of women’s empowerm... | [HAPPY WOMAN Executive Committee] [International Women’s Day Seminar] Mama Ogi will also be on stage! Improving self-esteem is the key to promoting women’s success
~The importance of women’s empowerment~Thinking about gender equality
*View ... |
| 04.03.2024 | Biopharmaceutical Innovations Lead the Way in Migraine Drugs Market Advancement | CAGR of 3.1% | Migraine is a clinical condition associated with painful headaches and other symptoms such as nausea, sensitivity to smell, and others.
PORTLAND, OREGON, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- Migraine drugs are medications that... |
| 06.02.2024 | Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023 | Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023
Tue, Feb 06, 2024 04:36 CET Report this content
Stockholm, Sweden, February 6, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their qua... |
| 09.01.2024 | Leqembi® approved for the treatment of Alzheimer’s disease in China | Leqembi® approved for the treatment of Alzheimer’s disease in China
Tue, Jan 09, 2024 09:30 CET Report this content
Stockholm, Sweden, January 9, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leq... |
| 07.11.2023 | Your morning biotech news roundup | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a CRISPR delay, some curious biotech language, and the derailment of a prom... |
| 20.10.2023 | Teddi Mellencamp Gets Naked for Melanoma Awareness Month | WASHINGTON (PRWEB) May 01, 2023 -- The Melanoma Research Foundation (MRF) is pleased to announce the launch of its annual award-winning #GetNaked campaign in recognition of Melanoma Awareness Month this May. TV personality, wellness coach, ... |
| 16.10.2023 | New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD | New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD
Mon, Oct 16, 2023 08:00 CET Report this content
Stockholm, October 16, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIO... |
| 19.07.2023 | Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023 | /EIN News/ -- Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer’s disease
New data on subcutaneous formulation shows promising PK /PD data modeling on effic... |
| 07.07.2023 | FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease | /EIN News/ -- The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease
The Centers for Medicare & Medicaid Services (CMS) annou... |
| 16.06.2023 | The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab | Over the past several months, my conversations with colleagues in the Alzheimer’s field have featured an unusual sentiment: optimism inflected with worry.
Optimism because, after years of failed studies and the disastrous accelerated approv... |
| 09.06.2023 | FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease | /EIN News/ -- Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease
The PDUFA action date for tr... |
| 17.05.2023 | Societal value of lecanemab in Japan published in Neurology and Therapy | Societal value of lecanemab in Japan published in Neurology and Therapy
Wed, May 17, 2023 01:30 CET Report this content
Stockholm, May 17, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication... |
| 08.05.2023 | BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH AN OPTION OF STRATEGIC COLLABORATION WITH EISAI FOR BB-1701 | HANGZHOU, China, May 8, 2023 /PRNewswire/ -- Bliss Biopharmaceutical (Hangzhou) Co., Ltd, ("BlissBio") a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced a cl... |
| 01.05.2023 | Teddi Mellencamp Gets Naked for Melanoma Awareness Month | WASHINGTON (PRWEB) May 01, 2023
The Melanoma Research Foundation (MRF) is pleased to announce the launch of its annual award-winning #GetNaked campaign in recognition of Melanoma Awareness Month this May. TV personality, wellness coach, hos... |
| 03.04.2023 | New lecanemab-data presented at the AD/PD™ 2023 conference | New lecanemab-data presented at the AD/PD™ 2023 conference
Mon, Apr 03, 2023 08:00 CET Report this content
Stockholm, April 3, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and its partner Eisai has presented new findings on lecanem... |
| 31.03.2023 | EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING | TOKYO and CAMBRIDGE, Mass., March 30, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. BIIB Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, &qu... |
| 31.03.2023 | Eisai publishes additional detailed analyses from lecanemab phase 2b study | Eisai publishes additional detailed analyses from lecanemab phase 2b study
Fri, Mar 31, 2023 08:00 CET Report this content
Stockholm, March 31, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today the public... |
| 31.03.2023 | Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals | TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. BIIB Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,... |
| 30.03.2023 | Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals | /EIN News/ -- TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Ch... |
| 23.03.2023 | EISAI TO PRESENT NEW LECANEMAB DATA, INCLUDING RESEARCH EVALUATING SAFETY PROFILE, CLINICAL OUTCOMES AND QUALITY OF LIFE MEASURES, AS WELL AS OTHER IMPORTANT ALZHEIMER'S DISEASE RESEARCH, AT THE AD/PD... | Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Patients from Eisai's Lecanemab Phase 3 Confirmatory Clarity AD Study in Early Alzheimer's Disease
TOKYO, March 22, 2023 /PRNewswire/ -- Eisai... |
| 20.03.2023 | EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL | TOKYO, March 19, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ) p... |
| 20.03.2023 | Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal | Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal
Mon, Mar 20, 2023 00:30 CET Report this content
Stockholm, March 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BI... |
| 06.03.2023 | FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease | Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval
Priority Review accelerates FDA review time with a Prescription Drug User Fee Act (PDUFA... |
| 07.01.2023 | Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease | Submission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and is based on data from the confirmatory Phase 3 Clarity AD clinical trial
TOKYO and CAMBRIDGE, Mass., Jan. 6, 2023 /PRNewswire/ -- Eisai Co.... |
